, Tracking Stock Market Picks
Enter Symbol:
Rating: DGX

Quest Diagnostics Incorporated (NYSE: DGX) reiterated to Neutral by Credit Suisse

Friday,  Sep 14, 2012  8:25 AM ET by Dave Ficere

Credit Suisse reiterated Quest Diagnostics Incorporated (NYSE: DGX) to Neutral.
Previously Credit Suisse rated Neutral with price target $58 Quest Diagnostics Incorporated (NYSE: DGX) on 10/21/2009, when the stock price was $56.75.

Quest Diagnostics Inc., is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care.

Excellence in equity and fixed income research is a hallmark of Credit Suisse. Globally, our equity research analysts provide in-depth coverage of over 2,500 companies and engage in a knowledge-sharing, value added culture that has yielded the most insightful product for our customers and tremendous competitive results. Additionally, Credit Suisse's powerful macro-economic and debt strategy teams integrate the bank's comprehensive company research with keen market perspectives of the ever-shifting investment terrain.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy